This website uses cookies. For more information please contact us or consult our privacy policy.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
- Home
- News and Insights
- Insights
- EU Financial Penalties for Centrally Approved Medicinal Products in Europe How to Prepare
EU Financial Penalties for Centrally Approved Medicinal Products in Europe - How to Prepare?
September 17, 2012 , Covington Advisory
May 8, 2016, Financial Times
Peter Bogaert and Grant Castle are quoted in a Financial Times article regarding the effect Brexit would have on the UK pharma industry. According to Bogaert, commenting on the important relationship between the European Medicines Agency and the UK’s Medicines and Healthcare Products Regulatory Agency, “Brexit would be a loss for both sides.” Castle adds that ...
August 1, 2012, Covington E-Alert
Belgium
2009/10, Life Sciences Handbook